DexCom earnings beat by $0.03, revenue topped estimates
New York-based investment firm Saba Capital Management, L.P., led by Boaz Weinstein, has reported the sale of 30,156 shares of abrdn Life Sciences Investors (NYSE:HQL), a $326 million market cap company known for its impressive 16.4% dividend yield. The transaction, which took place on April 10, 2025, was executed at a price of $11.14 per share, amounting to a total of $335,937. According to InvestingPro, HQL has maintained dividend payments for 30 consecutive years, making it a notable dividend aristocrat.
Following this transaction, Saba Capital holds 3,094,316 shares of abrdn Life Sciences Investors. The sale was disclosed through a Form 4 filing with the Securities and Exchange Commission, underscoring Saba Capital’s position as a significant shareholder in the company. Trading at a P/E ratio of 3.83 and with a beta of 0.77, the stock shows relatively low volatility compared to the broader market. Discover more key metrics and analysis with InvestingPro, which offers additional exclusive insights about HQL’s financial health and valuation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.